On August 1, 2019, the SEC filed a complaint in the United States District Court for the Southern District of New York against Adaptimmune Therapeutics, Inc. ("Adaptimmune") for violating the antifungal antifungal antifungal protocol.  The SEC's complaint alleges that Adaptimmune violated the antifungal antifungal protocol and failed to adequately assess the safety and efficacy of its products.  The SEC's complaint, filed in the U.S. District Court for the Southern District of New York, alleges that Adaptimmune failed to comply with the antifungal antifungal protocols and failed to adequately assess the safety of its products.  The SEC's complaint charges that Adaptimmune violated the antifungal protocol and failed to comply with the antifungal requirements.  The SEC's complaint, filed in federal court in New York, charges Adaptimmune with violations of the antifungal and antifungal antifungal provisions of Section 17(a) of the Securities Act of 1933 ("Securities Act") and Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act") and Rule 10b-5 thereunder.  Without admitting or denying the allegations in the SEC's complaint, Adaptimmune has agreed to the entry of a final judgment that permanently enjoins it from violating the antifungal provisions of Section 10(b) of the Exchange Act and Rule 10b-5 thereunder, and orders it to pay disgorgement of ill-gotten gains with prejudgment interest.  The settlement is subject to court approval.  The SEC's investigation, which is continuing, is being conducted by Waleed Abdel-Naby, Marc Frahm, and Madison Tapper of the SEC's Boston Regional Office.  The litigation will be led by Mr. Frahm and Mr. Tapper.  The SEC appreciates the assistance of the U.S. Attorney's Office for the Southern District of New York, the Federal Bureau of Investigation, and the U.S. Secret Service.